araag2/HINT huggingface dataset:
Clinical trial NCT02350569 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent or for those individuals where
             hepatic encephalopathy affects their ability to provide initial or ongoing consent,
             has an appropriate and legally-authorized representative (LAR) willing and able to
             provide consent on behalf of the individual.

          -  HCV RNA infection with quantifiable virus at screening

          -  Must have chronic genotype 1 or 4 HCV infection for ≥ 6 months by medical history or
             liver biopsy

          -  Currently on the liver transplantation wait list

          -  Screening electrocardiogram (ECG) without clinically significant abnormalities.

          -  A negative serum pregnancy test result is required for females

        Key Exclusion Criteria:

          -  Any previous solid organ transplant

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with participant's treatment, assessment, or compliance

          -  HIV infection or a positive hepatitis B virus surface antigen result

          -  History of malignancy (with exception of hepatocellular carcinoma within Milan
             criteria, certain resolved skin cancers or other early cancer for which surgical
             resection is considered to be completely curative)

          -  Treatment with any approved or experimental medication with known anti-HCV activity
             within 1 month prior to screening date

          -  Prior exposure to an HCV non-structural protein (NS)5A inhibitor

          -  Patients on hemodialysis prior to or at the time of transplantation will be excluded

          -  Creatinine clearance (CLcr) < 40 mL/min at screening or < 40 mL/min on day of
             transplant

          -  Participation in a clinical study with an investigational drug or biologic within 28
             days prior to screening visit

          -  Receipt or planned receipt of an organ from an HCV positive donor

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02351739 (phase 2, status: completed)
Conditions: metastatic urothelial carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: pembrolizumab, acp-196 in combination with pembrolizumab
SMILES: CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women ≥ 18 years of age

          -  Histologically or cytologically confirmed urothelial carcinoma of the bladder or mixed
             histology bladder cancer

          -  Metastatic bladder cancer with disease progression on or after platinum-based
             chemotherapy

          -  Any primary site of urothelial carcinoma including upper tract, renal pelvis, bladder,
             and ureters

          -  Prior therapy with ≥ 1 systemic chemotherapy regimens for urothelial carcinoma

          -  Presence of radiographically measurable disease (defined as the presence of ≥ 1 lesion
             that measures ≥ 10 mm [≥ 15 mm for lymph nodes]

          -  ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Prior malignancy (other than bladder cancer), except for adequately treated basal cell
             or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the
             subject has been disease free for ≥ 2 years of which will not limit survival to < 2
             years.

          -  Known central nervous system metastases and/or carcinomatous meningitis

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening
Clinical trial NCT02351882 (phase 2/phase 3, status: completed)
Conditions: alzheimer disease, agitation, weight loss, pain, oxidative stress
ICD codes: G30.8, G30.9, G30.0, G30.1, R45.1, R63.4, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: nabilone, placebo
SMILES: [H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females ≥55 years of age

          -  Diagnostic and Statistical Manual (DSM) -V criteria for Major Neurocognitive Disorder
             due to AD. Patients with both Major Neurocognitive Disorder due to AD and Major
             Vascular Neurocognitive Disorder (i.e., mixed AD and cerebrovascular disease) will
             also be included.

          -  Currently in moderate-to-severe stage of dementia (Mini-Mental Status Examination
             (MMSE) ≤24)

          -  Presence of clinically significant agitation (Neuropsychiatric Inventory (NPI)
             agitation subscale ≥3)

          -  If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or
             memantine), dosage must be stable for at least 3 months. If the ChEI and/or memantine
             has been discontinued, they may enroll after 1 month.

        Exclusion Criteria:

          -  Change in psychotropic medications less than 1 month prior to study randomization
             (e.g., concomitant antidepressants)

          -  Contraindications to nabilone (history of hypersensitivity to any cannabinoid)

          -  Current or past significant cardiovascular disease (e.g. uncontrolled hypertension,
             ischemic heart disease, arrhythmia and severe heart failure)

          -  Presence or history of other psychiatric disorders or neurological conditions (e.g.
             psychotic disorders, schizophrenia, stroke, epilepsy), previous or current abuse
             of/dependence on marijuana
Clinical trial NCT02352337 (phase 2, status: active, not recruiting)
Conditions: metastatic pancreatic cancer
ICD codes: C25.3
Drugs: folfirinox, lv5fu2, folfiri.3, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic disease

          -  At least one mesurable lesion according to RECIST V1.1 criteria

          -  No prior chemotherapy (excepted if there is at least on lestion out of the irradition
             area)

          -  Age > 18 years. A favorable adviced by an onco geriatrician would be mandatory for
             inclusion of patients older than 75 older

          -  Performance statut (WHO) 0-1

          -  Polynyclear ≥ 1500/mm3

          -  Bilirubine ≤ 1,5 fois la LSN, creatinin < 120μmol / L

          -  Signed informed consent form

        Exclusion Criteria:

          -  Another type of pancreas tumor, as endocrine tumor ou with acinous cells

          -  Ampulloma

          -  Cerebral or meningeal metastasis

          -  Gilbert disease

          -  Neuropathie > or = grade 1

          -  Study treatments contraindication

          -  Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction
             or bowel sub-obstruction no resolved with specific treatment

          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant
             disease prevent patient to receive study Cancer within the 5 years before inclusion,
             except for int situ cancer of the neck of the uterus or basal cell skin cancer

          -  Significant previous cardiac and respiratory disease

          -  Patient included in an other therapeutic study with experimental treatment

          -  Pregnancy or breast feeding

          -  Patient depreved of freedom or under gardianship

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule
Clinical trial NCT02352948 (phase 2, status: active, not recruiting)
Conditions: non - small cell lung cancer nsclc
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: medi4736 (durvalumab), vinorelbine, gemcitabine, erlotinib, medi4736 (durvalumab) in combination with tremelimumab (anti-ctla4), tremelimumab (anti-ctla4)
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Aged at least 18 years

          -  Documented evidence of NSCLC (Stage IIIB/ IV disease)

          -  Disease progression or recurrence after both a platinum-based chemotherapy regimen and
             at least 1 additional regimen for treatment of NSCLC

          -  World Health Organization (WHO) Performance Status of 0 or 1

          -  Estimated life expectancy more than 12 weeks

        Exclusion Criteria:

          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4

          -  Brain metastases or spinal cord compression unless asymptomatic, treated and stable
             (not requiring steroids)

          -  Active or prior documented autoimmune disease within the past 2 years

          -  Evidence of severe or uncontrolled systemic disease, including active bleeding
             diatheses or active infections including hepatitis B, C and HIV

          -  Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) >Grade 2
             from previous anti-cancer therapy

          -  Known EGFR TK activating mutations or ALK rearrangements

          -  Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
             immunotherapy agent, or any unresolved irAE >Grade 1

          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis)
Clinical trial NCT02354586 (phase 2, status: active, not recruiting)
Conditions: ovarian neoplasms, ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: niraparib
SMILES: NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.

          -  Patients of childbearing potential must have negative pregnancy serum test within 72
             hours of being dosed

          -  Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous
             epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent
             disease and must have been previously treated with chemotherapy and experienced a
             response lasting at least 6 months to first-line platinum based therapy.

          -  Patients Must have completed 3 or 4 previous chemotherapy regimens.

          -  Patients must have completed their last chemotherapy regimen > 4 weeks prior to
             treatment initiation.

          -  Patients must have measurable disease according to RECIST (v.1.1).

          -  Patients must have formalin-fixed, paraffin-embedded tumor samples available from the
             primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment
             initiation.

          -  Patients must agree to blood samples during screening and at the end of treatment for
             cytogenetic analysis.

        Exclusion Criteria:

          -  Patients must not have any known, persistent (> 4 weeks), ≥Grade 3 hematologic
             toxicity during the last cancer therapy. Patients must not have any known, persistent
             (>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.

          -  Patients must not have received pelvic radiotherapy as treatment for primary or
             recurrent disease within 1 year of the first dose of study treatment.

          -  Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.

          -  Patients must not be considered a poor medical risk due to a serious, uncontrolled
             medical disorder, nonmalignant systemic disease or active, uncontrolled infection.

          -  Patients must not have received a transfusion (platelets or red blood cells) within 4
             weeks of the first dose of study treatment.

          -  Patients must not have known history or current diagnosis of myelodysplastic syndrome
             (MDS) or acute myeloid leukemia (AML).
Clinical trial NCT02354976 (phase 2, status: completed)
Conditions: non-alcoholic fatty liver disease (nafld, hypertriglyceridemia
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: placebo, omega-3 carboxylic acid, fenofibrate 200mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: - Provision of informed consent

          -  Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated
             venepuncture

          -  Have serum triglycerides ≥1.7 mM

          -  Have liver fat content as assessed by MRI >5.5%

          -  Have a body mass index (BMI) >25 and ≤40 kg/m2

             , Exclusion Criteria: - History of or presence of any clinically significant disease
             or disorder which, in the opinion of the investigator, may either put the subject at
             risk because of participation in the study, or influence the results or the subject's
             ability to participate in the study.

          -  Creatinine clearance <60 mL/min at screening (Cockcroft-Gault formula).

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine
             aminotransferase (ALT) >3x ULN

          -  Total bilirubin >2.0 mg/dL (34.2 µmol/L)

          -  Type 2 diabetes, as defined by WHO criteria e.g. fasting plasma Glucose >7.0 mM or use
             of antidiabetic therapy

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator. This includes signs of liver disease
             other than NAFLD that motivates further investigations of treatment based on clinical
             judgement

          -  Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse was to
             be defined as >14 drinks per week (1 drink = 35 cl beer, 14 cl wine, or 4 cl hard
             liquor) or as judged by the investigator
Clinical trial NCT02355028 (phase 2, status: completed)
Conditions: exudative age-related macular degeneration
ICD codes: H35.3230, H35.3210, H35.3220, H35.3233, H35.3290, H35.3213, H35.3223
Drugs: lha510 ophthalmic suspension, lha510 vehicle, ranibizumab ophthalmic solution
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Sign written informed consent form;

          -  Wet AMD;

          -  IVT anti-VEGF therapy for at least 6 months and a maximum of 7 years since the 3rd
             loading dose;

          -  BCVA 50 letters (approximate Snellen equivalent 20/100) or better in the study eye;

          -  Demonstrate ability to administer eye drops (subject or care-giver);

          -  CNV recently demonstrated high need for frequent anti-VEGF therapy and a sustained
             functional and clear anatomical response to the therapy in the study eye;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Any active ocular or periocular infection or intraocular inflammation;

          -  Current or history of macular or retinal disease (if visually significant) other than
             wet AMD in the study eye;

          -  Current clinically significant vitreous hemorrhage or history of rhegmatogenous
             retinal detachment affecting the macula in the study eye;

          -  History of hypersensitivity to any of the study drugs or clinically relevant
             sensitivity to fluorescein dye or povidone iodine;

          -  Women of child-bearing potential;

          -  History of a medical condition that, in the opinion of the Investigator, would
             preclude scheduled study visits, completion of the study or a safe administration of
             investigational product;

          -  Other protocol-specified exclusion criteria may apply.
Clinical trial NCT02358096 (phase 2, status: completed)
Conditions: chronic kidney disease, type 2 diabetes
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: asp8232, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have an estimated glomerular filtration rate (eGFR) ) >=25 and <75
             ml/min/1.73m2.

          -  Subject must have a documented diagnosis of T2DM and received anti-diabetic medication
             (oral and/or parenteral) for at least 1 year prior to screening

          -  Subject's glycated hemoglobin (HbA1c) level is < 11.0% (<97 mmol/mol) at screening.

          -  Subject is on a stable therapy with an angiotensin-converting-enzyme (ACE) inhibitor
             or angiotensin receptor blockers (ARB) for at least 3 months prior to screening.

          -  Subject who receives anti-hypertensive treatment, non-insulin anti-diabetic agents
             and/or vitamin D receptor activators at screening needs to be on stable therapy for at
             least 3 months prior to screening. Subjects on insulin therapy may have the insulin
             type/dose/schedule adjusted even during the 3 months prior to screening.

          -  If the subject has been subjected to specific dietary interventions then this has to
             be stable over the past 3 months prior to screening visit.

          -  Subject's UACR is ≥ 200 and ≤ 3000 mg/g in a first morning void (FMV) sample at
             screening AND the geometric mean UACR of all FMV samples at visit 4 and at visit 5 is
             ≥ 200 and ≤ 3000 mg/g AND the UACR in at least 3 FMV samples at visit 4 and visit 5 is
             ≥ 200 mg/g.

        Exclusion Criteria:

          -  Subject is on, or previously received, renal replacement therapy (e.g. dialysis or
             kidney transplantation).

          -  Subject has obstructive uropathy or other causes of renal impairment not related to
             parenchymal renal disorder and/or disease of the kidney; or subject currently has or
             has had in the past renal disease secondary to malignancy.

          -  Subject's renal impairment and/or albuminuria is considered to be of other origin than
             Diabetic Kidney Disease.

          -  Subject has known (auto-) immune disorder and/or received immunosuppression for more
             than 2 weeks, cumulatively, within 12 weeks prior to screening or anticipated need for
             immuno-suppressive therapy during the study.

          -  Subject has active urinary tract infection which requires treatment or clinically
             significant infection at the time of screening or randomization

          -  Subject is diagnosed with type 1 diabetes mellitus or diabetes mellitus with unclear
             etiology.

          -  Subject has a sitting systolic blood pressure (SBP) <90 or >160 mmHg and/or a
             diastolic blood pressure (DBP) >90 mmHg at screening.
Clinical trial NCT02358538 (phase 2, status: active, not recruiting)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: ganaxolone
SMILES: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          1. Have parent or legal guardian available and willing to give written informed consent.

          2. Male and female outpatients between 2 and 18 years of age years of age at time of
             consent.

          3. Have any of the following epilepsy syndromes: PCDH19; CDKL5; Dravet Syndrome; Lennox
             Gastaut Syndrome (LGS); Continuous Spikes and Waves during Sleep (CSWS)

          4. Have uncontrolled cluster seizures and/or non-clustered seizures.

          5. Subjects should be on a stable regimen of anti-epileptic medication, and generally in
             good health.

          6. Parent or guardian is able and willing to maintain an accurate and complete daily
             written seizure calendar.

          7. Able and willing to take study medication with food, two or three times daily.

        Key Exclusion Criteria

          1. Have had previous exposure to ganaxolone.

          2. Known sensitivity or allergy to any component in the study drug, progesterone, or
             other related steroid compounds.

          3. Exposure to any investigational drug or device < 90 days prior to screening, or plans
             to participate in another drug or device trial at any time during the study.

          4. Concurrent use of vigabatrin, tiagabine, or ezogabine is not permitted.

          5. Have any medical condition that, in the investigator's judgment, is considered to be
             clinically significant and could potentially affect subject safety or study outcome,
             including but not limited to: clinically significant cardiac, renal, pulmonary,
             gastrointestinal, hematologic or hepatic conditions; or a condition that affects the
             absorption, distribution, metabolism or excretion of drugs.

          6. Have active suicidal plan/intent, or have had active suicidal thoughts in the past 6
             months or a suicide attempt in the past 3 years.

          7. Have Alanine transferase (ALT; SGPT) or Aspartate transferase (AST; SGOT) levels > 3
             times upper limits of normal (ULN), or total bilirubin >1.5 time ULN at the screening
             and baseline visits.